DUBLIN–(BUSINESS WIRE)–The “Klebsiella infections – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Klebsiella infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Klebsiella infections pipeline landscape is provided which includes the disease overview and Klebsiella infections treatment guidelines. The assessment part of the report embraces, in depth Klebsiella infections commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Klebsiella infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Klebsiella infections R&D. The therapies under development are focused on novel approaches to treat/improve Klebsiella infections.
Klebsiella infections Emerging Drugs Chapters
This segment of the Klebsiella infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Klebsiella infections Emerging Drugs
Kleb4V: LimmaTech Biologics
LimmaTech Biologics is developing Klebsiella pneumoniae tetravalent bioconjugate vaccine. LimmaTech Biologics uses a proprietary in vivo enzyme-based production method that alleviates the issues associated with the chemical conjugation process. At the core of this approach is a bacterial enzyme capable of forming precise linkages between glycan and protein moieties.
The versatility of this platform combined with our extensive glycoengineering experience enables the development of innovative vaccines for multiple pathogens that has not been possible previously. Kleb4V is currently in Phase I/II stage of development.
Klebsiella infections: Therapeutic Assessment
This segment of the report provides insights about the different Klebsiella infections drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Klebsiella infections
There are approx. 10+ key companies which are developing the therapies for Klebsiella infections. The companies which have their Klebsiella infections drug candidates in the most advanced stage, i.e. phase I/II include, LimmaTech Biologics.
PhasesThe report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Klebsiella infections Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- LimmaTech Biologics
- C3J Therapeutics
- Nosopharm
- Phico Therapeutics
- Locus Biosciences
- AKTHELIA
- Appili Therapeutics
- Debiopharm
- Affinivax
- Nomad Bioscience
Key Products
- Kleb4V
- ASP 1004
- NOSO-502
- LBP-KP01
- ATI-1503
- Debio 1454
- Research programme: Klebsiella and Pseudomonas vaccines
- Research programme: antibacterial biologics
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m2ff13
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900